Clinic
Langlade Hospital - Hotel Dieu of ST. Joseph of Antigo Wisconsin
Langlade Hospital - Hotel Dieu of ST. Joseph of Antigo Wisconsin was paid $19.58M by Medicaid between Jan 2018 and Dec 2024, across 190 billing codes. Its largest line is 99212, Office or other outpatient visit for the evaluation and management of an established patient, straightforward — 19% of everything it billed.
33Billing provider infoLANGLADE HOSPITAL - HOTEL DIEU OF ST. JOSEPH OF ANTIGO WISCONSIN
ANTIGO, WI 54409
ANTIGO, WI 54409
33aNPI1639187412assigned 08/04/2006
33bProvider typeRehabilitation Clinic/Center
28Total paid$19.58M
24GClaims424,014
24DCodes billed190
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rehabilitation Clinic/Center providers in Wisconsin
Rank by total paid#1 of 41
Median peer was paid$122K
This provider vs. median161×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official YANG, JERRY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 57,191 | $2.41M | |
| 2019 | 54,962 | $2.53M | |
| 2020 | 43,157 | $2.04M | |
| 2021 | 57,001 | $2.58M | |
| 2022 | 70,081 | $3.12M | |
| 2023 | 78,505 | $3.63M | |
| 2024incomplete | 63,117 | $3.28M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 19% | 25,756 | 21,953 | $3.78M |
| 96361 | Intravenous infusion, hydration; each additional hour | 10.0% | 5,748 | 4,511 | $1.95M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.7% | 16,939 | 13,660 | $1.89M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 8.8% | 18,065 | 15,343 | $1.72M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.8% | 11,601 | 9,865 | $1.53M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.1% | 23,837 | 21,424 | $1.19M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.2% | 6,147 | 5,394 | $813K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.6% | 4,877 | 3,974 | $705K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.2% | 3,757 | 2,879 | $630K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 3.1% | 6,007 | 5,237 | $616K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.0% | 3,428 | 2,380 | $582K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.3% | 3,196 | 2,299 | $451K |
178 more codes
| 99214 | Doctor's office visit, returning patient (more involved) | 1.5% | 7,809 | $296K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.5% | 1,434 | $290K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.4% | 2,731 | $278K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 580 | $181K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,402 | $164K |
| 80053 | Comprehensive metabolic panel | <1% | 19,894 | $154K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 10,098 | $141K |
| 87070 | <1% | 9,383 | $113K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 21,998 | $102K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,028 | $94K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 386 | $92K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 4,057 | $83K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,326 | $82K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,985 | $81K |
| 20610 | <1% | 490 | $74K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,834 | $71K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,410 | $63K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 5,198 | $63K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 645 | $62K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,651 | $61K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 302 | $60K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,061 | $56K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 382 | $52K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,765 | $43K |
| 80061 | Lipid panel | <1% | 3,667 | $39K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,677 | $39K |
| 84484 | <1% | 5,851 | $37K | |
| 81001 | <1% | 12,430 | $35K | |
| 81025 | <1% | 3,548 | $35K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 353 | $33K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 623 | $31K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 204 | $31K |
| 80306 | <1% | 2,226 | $29K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,637 | $29K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 5,422 | $27K |
| 71045 | Radiologic examination, chest; single view | <1% | 10,278 | $27K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,870 | $26K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,212 | $23K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 198 | $22K |
| 76801 | <1% | 250 | $20K | |
| 83690 | <1% | 4,011 | $19K | |
| 87077 | <1% | 2,588 | $17K | |
| 83605 | <1% | 2,886 | $17K | |
| 83880 | <1% | 1,158 | $17K | |
| 73630 | <1% | 1,176 | $15K | |
| 87040 | <1% | 2,554 | $15K | |
| 73030 | <1% | 1,072 | $15K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 134 | $14K |
| 73562 | <1% | 1,189 | $14K | |
| 76830 | Ultrasound, transvaginal | <1% | 126 | $13K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,454 | $13K |
| 85610 | <1% | 4,193 | $13K | |
| 87088 | <1% | 2,275 | $13K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 321 | $11K |
| 83735 | <1% | 3,302 | $11K | |
| 72100 | <1% | 498 | $11K | |
| 96367 | <1% | 127 | $11K | |
| 87186 | <1% | 2,062 | $11K | |
| 84702 | <1% | 761 | $10K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 136 | $10K |
| 85379 | <1% | 1,398 | $9K | |
| 87807 | <1% | 546 | $9K | |
| 85027 | <1% | 2,068 | $8K | |
| 73610 | <1% | 1,078 | $8K | |
| 74018 | <1% | 417 | $8K | |
| 12001 | <1% | 45 | $8K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 55 | $8K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 278 | $7K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,727 | $7K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 277 | $7K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 45 | $6K |
| 84439 | <1% | 762 | $5K | |
| 73130 | <1% | 548 | $5K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 67 | $4K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 476 | $4K |
| 84145 | <1% | 420 | $4K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,231 | $4K |
| 87210 | <1% | 727 | $4K | |
| 86140 | <1% | 1,386 | $4K | |
| 86850 | <1% | 546 | $4K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 75 | $3K |
| 84153 | <1% | 184 | $3K | |
| 82948 | <1% | 1,542 | $3K | |
| 82550 | <1% | 636 | $3K | |
| 73502 | <1% | 276 | $3K | |
| 81003 | <1% | 925 | $3K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 18 | $3K |
| 85007 | <1% | 1,092 | $3K | |
| 93793 | <1% | 342 | $3K | |
| 90715 | <1% | 111 | $3K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 446 | $2K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 62 | $2K |
| 85730 | <1% | 606 | $2K | |
| 74019 | <1% | 66 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,276 | $2K |
| 86618 | <1% | 126 | $2K | |
| 82553 | <1% | 340 | $2K | |
| 82962 | <1% | 847 | $2K | |
| 73110 | <1% | 222 | $2K | |
| 99337 | <1% | 185 | $1K | |
| 83540 | <1% | 312 | $1K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 14 | $1K |
| 84460 | <1% | 329 | $1K | |
| 76642 | <1% | 18 | $1K | |
| 86900 | <1% | 600 | $1K | |
| 83550 | <1% | 231 | $1K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 567 | $1K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,741 | $1K |
| 85652 | <1% | 701 | $1K | |
| 87468 | <1% | 62 | $1K | |
| 87484 | <1% | 62 | $1K | |
| 87469 | <1% | 62 | $1K | |
| 93971 | <1% | 18 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,079 | $1K |
| 86901 | <1% | 600 | $1K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 388 | $1K |
| 82565 | <1% | 191 | $1K | |
| 82803 | <1% | 73 | $898.59 | |
| 85018 | <1% | 243 | $779.42 | |
| 80050 | General health panel | <1% | 133 | $737.24 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 81 | $692.44 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,124 | $674.18 |
| 87205 | <1% | 206 | $651.68 | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 81 | $637.50 |
| 86308 | <1% | 73 | $572.47 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 407 | $475.88 |
| 72040 | <1% | 14 | $418.80 | |
| 36592 | <1% | 1,199 | $417.44 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,998 | $416.51 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 138 | $377.69 |
| 84703 | <1% | 64 | $353.18 | |
| 82375 | <1% | 18 | $322.22 | |
| 96376 | <1% | 1,100 | $302.98 | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 12 | $232.26 |
| 73140 | <1% | 62 | $208.14 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,728 | $190.09 |
| 36000 | <1% | 378 | $183.51 | |
| 99152 | <1% | 111 | $175.16 | |
| 82950 | <1% | 31 | $164.18 | |
| 82150 | <1% | 28 | $149.08 | |
| 99442 | <1% | 26 | $126.36 | |
| 87075 | <1% | 15 | $103.77 | |
| 73560 | <1% | 21 | $70.82 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,923 | $68.61 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 12 | $61.18 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,299 | $53.48 |
| 80076 | <1% | 17 | $52.32 | |
| 82043 | <1% | 13 | $45.95 | |
| A9270 | Non-covered item or service | <1% | 811 | $43.71 |
| 82947 | <1% | 12 | $43.04 | |
| 82248 | <1% | 15 | $42.77 | |
| 82570 | <1% | 12 | $35.42 | |
| G0008 | Administration of influenza virus vaccine | <1% | 25 | $32.20 |
| 99406 | <1% | 18 | $31.89 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,555 | $15.81 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 342 | $13.70 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 251 | $13.13 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,076 | $12.97 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 165 | $10.93 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,014 | $10.53 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 331 | $4.01 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 205 | $3.87 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 143 | $3.64 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 107 | $0.91 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 163 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 693 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 56 | $0.00 |
| G0378 | Hospital observation service, per hour | 0% | 26 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 15 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 15 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 26 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 44 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 59 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 18 | $0.00 |
| 73590 | 0% | 18 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 16 | $0.00 |
| E0114 | Crutches underarm, other than wood, adjustable or fixed, pair, with pads, tips and handgrips | 0% | 15 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialYANG, JERRY (SVP & CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.